INTRODUCTION AND OBJECTIVES: Ki-67 is known to be useful in estimating the fraction of proliferation tumor cells in various malignancies. We tried to investigate clinical association of Ki-67 (MIB-1) expression with the oncological outcomes in patients with localized prostate cancer (PCa) after the radical prostatectomy (RP).
METHODS: We retrospectively analyzed the data of 1,561 patients who underwent RP for localized PCa. According to the propensity score having Ki-67 expression, 183 patients with positive Ki-67 expression were matched to 549 patients without Ki-67 expression. By Using multivariate Cox-proportional hazards models and logistic regression tests, the prognostic value of each variables were tested.
RESULTS: After propensity score matching, positive Ki-67 group showed significant worse clinical characteristics and pathologic outcomes than negative Ki-67 group. The multivariate analysis showed that the Ki-67 expression was significantly associated with several adverse pathologic outcomes including higher pathologic stage (p [ 0.006), higher Gleason score (p [ 0.005), seminal vesicle invasion (p [ 0.036), and positive surgical margin (p [ 0.025). The group with Ki-67 expression showed significant worse biochemical recurrence-free survival (p<0.001) than negative Ki-67 group. Subsequent multivariate Cox analyses showed that Ki-67 was independent predictor for BCR after RP (HR 1.506, 95% CI 1.150 e 1.974, p < 0.001).
CONCLUSIONS: In our study, high Ki-67 expression was significantly related with adverse pathological and finally with worse biochemical recurrence-free survival. Further studies are needed to validate the prognostic value of Ki-67 more exactly in PCa patients. remains a disease with significant morbidity and mortality. To prevent a rise in CaP morbidity and mortality, prostate specific antigen (PSA) screening cannot be abandon, despite recent screening recommendations. However, a significant portion of men are over treated and over screened for indolent CaP. Although PSA screening saves lives, there remains a need to better identify men who will develop lethal CaP. Multiple biomarkers and multiparametric magnetic resonance imaging (mpMRI) have been developed that may aid in this advancement.
METHODS: PSA, 4K score, (Michigan Prostate Score) MiPS and mpMRI were retrospectively reviewed from a prospectively collected and maintained database according to the clinical pathway shown in Figure 1 . Data was analyzed for the ability of each biomarker to predict prostate cancer, GS 3þ4 prostate cancer and PI-RADS 3 or greater lesion on mpMRI in 36 patients. Overall and grade group (GG) 2þ CaP detection rates were determined. Patients were grouped into CaP positive, negative and MRI negative groups. All groups were compared using nested linear models. Post-hoc analysis was then performed to compare individual groups.
RESULTS: 65% and 58% of men were diagnosed with CaP and GG2þ CaP, respectively. Cohort data and biopsy data are shown in Table 1 and 2. Patients with CaP were more likely to have higher MiPS high-grade CaP %, higher MiPS CaP % and PSAD (p<0.05) compared to those without prostate cancer. Notably, there was no difference in 4K score, MiPS overall and high-grade cancer % between those without cancer and those with a negative mpMRI.
CONCLUSIONS: The use of 4K score, MiPS score and mpMRI compared to traditional PSA screening alone provided a greater clinically significant prostate cancer detection rate compared to traditional positive biopsy rates.
